Formulated to help transport fatty acids into cells for energy, it assists your body in making the most of every workout while supporting overall endurance and recovery
It can happen if the dose is too low, too high, or not effective for a particular patient
Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes
Helps metabolize fats and lose weight.
Environ Health Perspect, 101(suppl 4): 39-48
Heart Health Benefits Studies show that in addition to sustainable weight loss, these programs may reduce the risk of cardiovascular events, such as heart attacks, in high-risk individuals